Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine

Leuk Lymphoma. 2024 Jan;65(1):128-131. doi: 10.1080/10428194.2023.2264427. Epub 2024 Jan 10.

Authors

Takeo Yasu^{1

2

3}, Yoshito Gando¹, Mikio Shirota^{2

3}, Nobuharu Kosugi⁴, Masayuki Kobayashi^{2

4}

Affiliations

¹ Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Tokyo, Japan.
² Bokutoh Hospital-Meiji Pharmaceutical University Joint Research Center, Tokyo, Japan.
³ Department of Pharmacy, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
⁴ Department of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.

PMID: 37797220
DOI: 10.1080/10428194.2023.2264427

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Azacitidine / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
C-Reactive Protein*
Humans
Leukemia, Myeloid, Acute* / chemically induced
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Sulfonamides*

Substances

venetoclax
C-Reactive Protein
Azacitidine
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides